Although the exact mechanism of action has not been fully elucidated, bendamustine is an alkylator that appears to be structurally and mechanistically distinct from agents historically used in CLL treatment. Bendamustine induces extensive and durable double-stranded DNA breaks that result in initiation of...
Emerging Treatment Options for Patients With CLL Clinical Thought Released: April 21, 2022 Expires: April 20, 2023 View Activity Cases in CLL: Frontline Therapy Selection and Clinical Trial Considerations for a Patient With Multiple Comorbidities Clinical Thought Released: July 07, 2022 Expires:...
Background: The population of patients with chronic lymphocytic leukemia (CLL) with disease refractory to Bruton tyrosine kinase inhibitors (BTKi) is growing given the widespread use of these agents. We conducted a single center study to evaluate the disease characteristics, treatment strategies, and...
EP: 7.Expert Perspectives: Navigating the Emerging Treatment Landscape of Combination Therapies in TN CLL—Applying Evidence to Clinical Practice EP: 8.Expert Insights: Treatment Selection in Second-Line R/R CLL and Limitations of Applying MAIC Data in the Real-World Practi...
LAVA expects to file an Investigational New Drug (IND) application with the U.S. Food and Drug Administration (FDA), which, if accepted, will subsequently include patients in the United States. In October 2021, the FDA granted orphan drug designation ...
More than 20,000 people in the US are diagnosed with CLL or SLL each year.2 The disease is considered relapsed when it returns after a period of remission and refractory when it does not respond to treatment. IOV-CLL-01 trial overview Iovance is conducting a Phase 1/2 trial to evaluate...
Medical Crossfire®: Expert Interpretations of the Latest Data in CLL Management – Understanding the Impact of Optimal Treatment Selection on Patient Outcomes View More Virtual Testing Board: Digging Deeper on Your Testing Reports to Elevate Patient Outcomes in Advanced Non–Small Cell Lung Cancer ...
Current evidence for treatment with nusinersen for spinal muscular atrophy: a systematic review. Acta Neurol. Belg. 119, 523–533 (2019). PubMed Google Scholar Sivaramakrishnan, M. et al. Binding to SMN2 pre-mRNA-protein complex elicits specificity for small molecule splicing modifiers. Nat. ...
Ibrutinib and venetoclax for first-line treatment of CLL. N. Engl. J. Med. 380, 2095–2103 (2019). Article CAS PubMed Google Scholar Zelenetz, A. D. et al. Venetoclax plus R- or G-CHOP in non-Hodgkin lymphoma: results from the CAVALLI phase 1b trial. Blood 133, 1964–1976 (...
Latest Conference Coverage Overview of iMMagine-1 Trial: Phase 2 Registrational Study of Anitocabtagene Autoleucel for the Treatment of R/R MM Application of Real-World Evidence in Selecting CAR T in R/R MM Addition of Daratumumab to Lenalidomide Maintenance Boosts MRD-Negative Conversions in ...